Acute myeloid leukemia commentary

Robert J. Arceci

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

An ever increasing number of molecular signatures are continuing to demonstrate the profound heterogeneity that characterizes acute myeloid leukemia (AML). The first significant advance in inducing remission in patients with AML included the combination of 7 days of cytosine arabinoside (ARAC) at 100 mg/m2 by continuous infusion along with three initial days of daunomycin at 45 mg/m2

Original languageEnglish (US)
Title of host publicationEvidence-Based Pediatric Oncology
Subtitle of host publicationThird Edition
PublisherJohn Wiley and Sons
Pages117-125
Number of pages9
ISBN (Print)9780470659649
DOIs
StatePublished - May 8 2013

Keywords

  • Acute myeloid leukemia (AML)
  • Allogeneic transplantation
  • Hematopoietic stem cell transplantation (HSCT)
  • Postremission therapy
  • Remission

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Acute myeloid leukemia commentary'. Together they form a unique fingerprint.

  • Cite this

    Arceci, R. J. (2013). Acute myeloid leukemia commentary. In Evidence-Based Pediatric Oncology: Third Edition (pp. 117-125). John Wiley and Sons. https://doi.org/10.1002/9781118625309.ch12